Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Companies Coronavirus COVID-19

Lilly’s Zepbound: The Biggest-Selling Drug In The World, Ever?

  • Data

Executive Summary

Humira currently holds the record as the bestselling drug ever. But Keytruda is coming for its crown – and beyond that, Zepbound.

You may also be interested in...



Syngene Eyes Sweet Spot As New Modalities Hog Limelight

Syngene’s CEO discusses its work in ADC development and trends in the CRDMO space as US biotechs navigate a funding squeeze and manufacturing opportunities loom in areas like GLP- 1 receptor agonists.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?

Industry Leaderboard Gains And Dips Were Still Marked By COVID-19

Pfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.

Table

View full table

Topics

Related Companies

Tags:
Commercial Companies Coronavirus COVID-19
Latest Headlines

China Seniors' Rising HIV Rates Pose Control Challenges

Seismic Rumbles Into Clinic With $121m For Novel Immunology Biologics

EyePoint Hits New Durability Milestone For Wet AMD Treatment

Roche Looks To Muscle Into Obesity Market With $2.7bn Carmot Buyout

See All
UsernamePublicRestriction

Register

SC149362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By